Opinion: Letting academic medical centers make CAR-T drugs would save billions
We took a fork in the CAR-T road a few years back and went the wrong way. It's time to let academic medical centers once again make these lifesaving treatments.
by David Mitchell and Saad Kenderian and S. Vincent Rajkumar
Nov 20, 2019
3 minutes
Draw blood from someone with cancer. Engineer their blood cells to seek and destroy cancer. Reinfuse the cells and watch the cancer melt away. Chimeric antigen receptor T cell therapy (CAR-T) sounds like science fiction. But it’s the next frontier in cancer therapy.
We’re weaponizing individuals’ immune systems to destroy cancer and add years to their lives. It’s incredibly exciting. But at hundreds of thousands of dollars per dose, insurance companies and the U.S. government are struggling to figure out how to for these breakthrough treatments.
You’re reading a preview, subscribe to read more.
Start your free 30 days